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DOI 10.1186/s13048-014-0110-6RESEARCH Open AccessThe transcriptome of corona radiata cells from
individual MІІ oocytes that after ICSI developed to
embryos selected for transfer: PCOS women
compared to healthy women
Marie Louise Wissing1*, Si Brask Sonne2, David Westergaard3, Kho do Nguyen4, Kirstine Belling3, Thomas Høst1
and Anne Lis Mikkelsen1Abstract
Background: Corona radiata cells (CRCs) refer to the fraction of cumulus cells just adjacent to the oocyte. The CRCs
are closely connected to the oocyte throughout maturation and their gene expression profiles might reflect oocyte
quality. Polycystic ovary syndrome (PCOS) is a common cause of infertility. It is controversial whether PCOS associate
with diminished oocyte quality. The purpose of this study was to compare individual human CRC samples between
PCOS patients and controls.
Methods: All patients were stimulated by the long gonadotropin-releasing hormone (GnRH) agonist protocol.
The CRC samples originated from individual oocytes developing into embryos selected for transfer. CRCs were
isolated in a two-step denudation procedure, separating outer cumulus cells from the inner CRCs. Extracted
RNA was amplified and transcriptome profiling was performed with Human Agilent® arrays.
Results: The transcriptomes of CRCs showed no individual genes with significant differential expression
between PCOS and controls, but gene set enrichment analysis identified several cell cycle- and DNA replication
pathways overexpressed in PCOS CRCs (FDR < 0.05). Five of the genes contributing to the up-regulated cell cycle
pathways in the PCOS CRCs were selected for qRT-PCR validation in ten PCOS and ten control CRC samples.
qRT-PCR confirmed significant up-regulation in PCOS CRCs of cell cycle progression genes HIST1H4C (FC = 2.7),
UBE2C (FC = 2.6) and cell cycle related transcription factor E2F4 (FC = 2.5).
Conclusion: The overexpression of cell cycle-related genes and cell cycle pathways in PCOS CRCs could indicate a
disturbed or delayed final maturation and differentiation of the CRCs in response to the human chorionic gonadotropin
(hCG) surge. However, this had no effect on the in vitro development of the corresponding embryos. Future studies are
needed to clarify whether the up-regulated cell cycle pathways in PCOS CRCs have any clinical implications.
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Polycystic Ovary Syndrome (PCOS) is the most preva-
lent endocrine disorder of women in the reproductive
age and represents a combination of polycystic ovaries,
oligo/anovulation and hyperandrogenism [1]. The follicu-
lar microenvironment previously found to be altered in
PCOS women might influence oocyte maturation and oo-
cyte developmental competence [2,3]. Previous studies of
PCOS women compared to healthy women revealed gene
expression differences in metaphase ІІ (MII) oocytes [4],
in cumulus cells of individual MІІ oocytes with unknown
developmental potential [5] and pooled, cultured cumulus
cells [6]. Ribosomal RNA content was increased in cumu-
lus cells of PCOS women [7], which could indicate a
higher rate of proliferation; also granulosa cells from PCOS
women have been shown to be hyperproliferative [3].
These alterations may suggest an altered oocyte quality in
PCOS patients compared to controls. However, they do
not necessarily extrapolate to the clinical situation, where
only oocytes developing into top quality embryos are used
for transfer. A meta-analysis showed that PCOS women
had a similar number of top quality embryos and similar
rates of pregnancy and live births compared to healthy
women undergoing in vitro fertilization (IVF), but PCOS
patients had more oocytes retrieved and a significantly
lower fertilization rate [8].
Corona radiata cells (CRCs) refer to the innermost layer
of the cumulus cells, which is in direct contact with the
zona pellucida of the oocyte. Throughout folliculogenesis
and until the luteinizing hormone (LH) surge for final oo-
cyte maturation, transzonal projections exist between the
oocyte and the CRCs, allowing exchange of substances
between the oocyte and the CRCs [9]. We hypothesize
that transcriptomic analysis of CRCs would serve as a
non-invasive method of gaining deeper understanding of
the microenvironment of the oocyte. Since PCOS and
non-PCOS women undergoing IVF had the same clinical
outcome [8], we wanted to find out whether the transcrip-
tomic profile of CRCs would differ between PCOS and
controls in clinically relevant samples of CRCs from em-
bryos chosen for transfer.Materials and methods
This study was approved by The Danish Ethical Science
Committee (SJ-156) and conducted in accordance with the
Helsinki Declaration and all participants gave informed
consent before inclusion in the study.Study population
Ten women with PCOS and ten healthy, regularly cycling
women without known disease (controls) were included. Ex-
clusion criteria were diabetes type 1 or 2, impaired thyroid,
renal or hepatic function, congenital adrenal hyperplasia,endometriosis, premature ovarian failure, hypothalamic
amenorrhea or age >35 years.
Diagnosis of PCOS was made according to the Rotterdam
Consensus Criteria [1]. For all control women, indication
for intracytoplasmic sperm injection (ICSI) was a partner
with infertility (defined as <5 million progressively moving
spermatozoa/ml). For the PCOS women, half (5/10) of
the couples were referred to ICSI because of male infertil-
ity and the rest after 4–6 failed attempts of intra-uterine
insemination (IUI).
Baseline examination
Participants were included in the study based on a fo-
cused gynecological history and objective examination
including transvaginal ultrasound of the ovaries and
uterus. Blood samples were drawn after an overnight fast
at 08.30-09.00 a.m. on cycle day (cd) 3–5 for regularly cyc-
ling women and on a random day for amenorrhoeic women.
All androgen analyses were done at the same laboratory
(Statens Serum Institut, SSI, Copenhagen, Denmark) in
order to minimize variability. Total testosterone was mea-
sured by the CHS™ MSMS Steroids Kit (PerkinElmers®,
Waltham, Massachusetts, USA) with intra-assay variation
of 9.6% and inter-assay variation of 10.6%. Sex hormone-
binding globulin (SHBG) was measured by Architect i2000
analyzer (Abbott®, Abbott Park, Illinois, USA) with an
intra-assay variation of 2.8% and an inter-assay variation
of 5.8%. Free testosterone was calculated from total tes-
tosterone and SHBG [10]. LH and follicle-stimulating
hormone (FSH) were measured by immunoassay (LH:
ref 11732234, FSH: ref 11775863, Roche Diagnostics,
Mannheim, Germany).
Ovarian stimulation
Ovarian stimulation was achieved by the long gonadotropin-
releasing hormone (GnRH) agonist protocol. Pituitary
desensitization with buserelin 0.5 mg (Suprefact®, Sanofi-
Aventis, Paris, France) was started on cd 21 in regularly
menstruating women and at cd 15 for oligo/amenorrhoeic
women starting with ethinylestradiol 30 mg/desogestrel
150 mg daily from the 1st day of bleeding (Marvelon®,
Organon/Microgyn®, Bayer Pharma, Leverkusen, Germany)
and until cd 21. Controlled ovarian stimulation with recom-
binant FSH (rFSH) (Puregon®, Organon, Oss, Netherlands)
was started after at least 14 days of desensitization. Fol-
licle growth was monitored by transvaginal ultrasound. Re-
combinant human chorionic gonadotropin (rhCG) 6500 IU
(Ovitrelle®, Modugno, Italy) was administered when at least
three follicles reached the size of 17 mm. Oocyte Pick-up
(OPU) was performed 36 hours later under transvagi-
nal ultrasound guidance. Luteal phase support (Lutinus®,
Ferring©, Copenhagen, Denmark) was given from the day
of transfer and until the pregnancy test. We adhered to
the Danish National Criteria of elective single transfer for
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performed three weeks after a positive hCG blood test to
confirm intrauterine clinical pregnancy.
Isolation of corona radiata cells, fertilization and time
lapse incubation of embryos
Following OPU, cumulus-oocyte complexes were washed
several times in Fertilization medium (Cook, Eight Mile
Plains, Queensland, Australia) to remove cell debris, and
incubated for two hours in Fertilization medium (Cook,
Eight Mile Plains, Queensland, Australia). Then the oo-
cytes were transferred to a droplet of Cleavage medium
(Cook, Eight Mile Plains, Queensland, Australia) and
denudated in a two-step procedure: First, the cumulus
cells were removed by gentle pipetting in 20 μl Cumulase®
(Origio, Måløv, Denmark) with a 1–10 μl Eppendorf
Pipette using a Dual filter PCR clean 20 μl tip (Eppendorf,
Hamburg, Germany). Then the oocyte with the remaining
CRCs was transferred to 10 μl Cumulase® (Origio, Måløv,
Denmark) and the CRCs were removed by gentle pipet-
ting with a Denudation pipette 0.134-0.145 mm (Vitrolife,
Göteborg, Sweden). Immediately after oocyte denudation,
individual droplets containing the CRCs were transferred
to DNA Lobind Eppendorf tubes (Eppendorf, Hamburg,
Germany), snap frozen in liquid nitrogen and stored
at −80°C until RNA extraction. MΙΙ oocytes were fertil-
ized by ICSI within ten minutes after denudation, and in-
cubated in individual wells in an Embryoscope® (Unisense
Fertilitech, Aarhus, Denmark), which gave the opportunity
to track the development of all fertilized oocytes until
transfer (day 2), or, for the untransferred embryos, until
vitrification as top quality blastocyst or disposal at day 5/6.
Analysis of the images was done with the EmbryoViewer®
Software (Unisense FertiliTech Aarhus, Denmark). The
time from ICSI to the following events were annotated:
Pronuclei breakdown (defined as the first picture frame
where the pronuclei disappeared), 1st cleavage (defined as
the first picture frame where the zygote turned into two
cells) and cleavage to four cells (defined as the first picture
frame where four cells were observed the first time).
Selection of CRC samples used in the study
The CRC samples used in this study came from oocytes
developing into top quality embryos: All transferred em-
bryos were top quality embryos according to the ALPHA/
ESHRE consensus [11] scoring points in short: Four cells
at day 2, low fragmentation (cut-off 25% fragmentation),
cell cycle specific cell size, no multinucleation. Vitrified
top quality blastocysts day 5/6 had score 3–6 AA/AB
according to the blastocyst classification proposed by
Gardner and Schoolcraft [12]. The fate of the ten oocytes
corresponding to the CRC samples used were as follows:
In the PCOS group, ten transferred embryos gave three
clinical pregnancies, resulting in two live births and onemissed abortion in gestational week 7 and seven negative
hCG tests 14 days after oocyte retrieval; In the control
group, three top quality blastocysts were vitrified for later
use, and seven transferred embryos gave three clinical
pregnancies with two live births and one missed abortion
in gestational week 7.
RNA extraction and amplification
Total RNA was extracted by the RNAequeous® micro-kit
from Ambion (Life Technologies, Paisley, UK) according
to manufacturer’s instructions. The samples were analyzed
for total RNA concentration by Qubit® (Life Technologies,
Paisley, UK) and total RNA quality and level of degrad-
ation using an Agilent 2100 Bioanalyzer and RNA 6000
Pico LabChip according to the manufacturer’s instructions
(Agilent Technologies, Waldbronn, Germany). All of the
RNA samples showed two distinct peaks representing 18S
and 28S rRNA, which indicated good quality RNA and
presented RNA Integrity Number (RIN) from 6–9.4. Total
RNA of 50 ng was amplified and converted into cDNA
using the Ovation Pico WTA System V2 RNA Amplifica-
tion System from NuGEN® Inc. (NuGEN®, San Carlos,
California, USA).
Microarray experiment
cDNA was coupled to a Cyanine 3-dUTP fluorescent
dye (Cy3) using the Oligonucleotide Array-Based CGH for
Genomic DNA Analysis, Enzymatic Labeling for Blood,
Cells or Tissues (protocol version 6.2, Agilent Technologies,
Santa Clara, California, USA). Cy3-labeled cDNA was hy-
bridized to Agilent Human Gene Expression Microarrays
4 × 44k v2 (G4845A) using the One-Color Microarray-
Based Gene Expression Analysis, Quick Amp Labeling
(version 5.7 protocol, Agilent Technologies, Santa Clara,
California, USA) and scanned using an Agilent DNA
Microarray scanner (Agilent Technologies, Santa Clara,
California, USA). For microarray analysis, we used six CRC
samples from PCOS women, and six from healthy controls
(12 arrays in total).
Quantitative reverse-transcriptase PCR
The following TaqMan® Gene Expression Assays (pre-
designed) (Applied Biosystems, Life Technologies Europe,
Nærum, Denmark) were used (Assay ID-No: Hs00168719_m1
(Cyclophillin B/PPIB), Hs00171034_m1 (Cyclin T2, CCNT2),
Hs00543883_s1 (histone cluster 1, H4c/HIST1H4C),
Hs00608098_m1 (E2F transcription factor 4, p107/p130-
binding/E2F4), and Hs00964100_g1 (ubiquitin-conjugating
enzyme E2C/UBE2C)). Sample triplicates were prepared
according to the manufacturer’s instructions. A total reac-
tion volume of 20 μL was prepared on ice containing
10 μL TaqMan® Gene Expression Master Mix (2X), 1 μL
TaqMan® Gene Expression Assay Mix (20X), 4 μL cDNA
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then centrifuged at 1,100 × g at 4°C for 5 minutes.
Gene expression was quantified using the MX3005
qPCR system (Agilent Technologies Denmark, Hørsholm,
Denmark) under the following thermal cycling conditions:
95°C for 10 minutes, 40 cycles of 95°C for 15 seconds and
60°C for 1 minute. The data was normalized to cyclophillin
(PPIB) [13], and relative quantification calculated accord-
ing to the Comparative CT Method (ABI user bulletin # 2,
2001). qRT-PCR was performed on ten PCOS CRC sam-
ples and ten control CRC samples.
Gene expression microarray processing and analysis
Array quality was assessed with the arrayQualityMetrics
R package [14], which used a variety of statistical tests
combined with data visualization to mark outliers. Evalu-
ation was done manually on a per array basis. Pre-processing
of microarray data was done with the LIMMA soft-
ware [15,16] available from the Bioconductor project
[17]. Normalization between arrays was done by quantile
normalization [18]. For genes with multiple probes, the in-
tensity was defined as the median of all probes mapping
to that gene.
Statistically significant differences between PCOS and
control CRC samples in expression of individual tran-
scripts were assessed by the LIMMA moderated t-test
[16] using the Benjamin-Hochberg method of correction
of P-values for multiple testing.
Statistical significance of biological themes was investi-
gated for the entire dataset with the Gene Set Enrichment
Analysis (GSEA) software version 2.0.12 (http://www.
broadinstitute.org/gsea/index.jsp) [19,20]. In short, the
GSEA algorithm ranked genes according to their expres-
sion level. By default, genes were ranked using the Signal-
2-Noise metric, a more robust measure than both mean
and median values, and very robust against outliers:
Signal2Noise ¼ μpcos−μcontrol
sdpcos þ sdcontrol
The enrichment of a pathway was assessed by walking
through the list of ranked genes, incrementing a running
sum score when encountering a gene found in the path-
way, and decreasing it when encountering a gene not in
the pathway. According to the authors, this corresponded
to a weighted Kolmogorov-Smirnov-like statistic. Statis-
tical significance was assessed by permutating the ranked
list of genes a thousand times. Genes which were either
poorly expressed, had high intra-variation in the group or
had low variance between the PCOS and control group
populated the middle of the ranked list, and thus did not
contribute to the running sum score. We specifically in-
vestigated the pathways contained in the databases KEGG[21] and REACTOME [22]. Normalized enrichment score
(NES) is defined as:
NES ¼ actual ES
mean ESs against all permutations of the datasetð Þ
NES was reported together with the false discovery
rate (FDR). We reported pathways with FDR ≤0.05.
All samples were MIAME compliant and were handled
according to SOP in the microarray Center. The 12 ar-
rays were submitted to ArrayExpress (http://www.ebi.ac.
uk/arrayexpress/) at EMBL using MIAMExpress. The ex-
periment accession number is E-MEXP-3985.
Statistics
Differences in baseline parameters between groups were
tested by Mann–Whitney test (Graphpad Prism v. 6, San
Diego, California, USA). Differences between groups in
developmental timing of the embryos corresponding to
the selected CRC samples were evaluated by Students t-
test (Graphpad Prism v. 6, San Diego, California, USA).
Differences between PCOS and control CRC samples in
gene expression of selected genes in the qRT-PCR ex-
periment were evaluated by Bayesian parameter estima-
tion [23]. A comparison was considered significant if the
95% HDI (Highest Density Interval) did not contain the
value 0.
Results
Baseline parameters of study groups
The PCOS and control group differed according to PCOS
status. The PCOS group exhibited oligomenorrhea, poly-
cystic ovaries and hyperandrogenaemia (Table 1). Age,
BMI and basal FSH were similar across groups (Table 1).
Embryo kinetic timings of the embryos corresponding
to the selected CRC samples did not differ between groups
(Table 1).
Quality of the arrays
There were no apparent outliers based on the arrayQua-
lityMetrics reports.
Differentially expressed genes
After correction for multiple testing, no individual genes
in the microarray experiment showed significant differ-
ential expression between PCOS CRC samples and con-
trol CRC samples (Additional file 1).
Gene set enrichment analysis
GSEA showed upregulation of 24 pathways with FDR <
0.05 in PCOS CRCs compared to control CRCs (Table 2).
Especially pathways involved in cell cycle and DNA rep-
lication were up-regulated in PCOS CRCs (Table 2).
Additional file 2 shows the full pathway list with the
Table 1 Baseline descriptive parameters of the study participants and the average developmental timings of the
embryos corresponding to the CRC samples used in the study
PCOS Controls p-value
Age 27,3±3,4 27,8±4 ns
BMI 24±4,8 22,4±3,5 ns
No of antral follicles/ one plane 15,8±5,4 8,2±1,7 <0,0001
No of menstrual bleedings/year 1,8±3,2 12±0 <0,0001
Total testosterone 2,8±1,1 1,2±0,3 0,0003
Free testosterone 0,03931±0,02532 0,014±0,0042 0,0029
SHBG 78±26 79±21 ns
LH/FSH 1,6±0,8 0,8±0,3 0,03
Time of 2PN breakdown (h) 23.2±3.8 21.8±2.4 ns
Time of 1st Cleavage (h) 26±4.1 24.3±2.5 ns
Time of cleavage to 4 cells (h) 38.3±5 36.4±4.2 ns
p-value <0,05 considered significant. Not significant = ns.
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Pathway No of genes enriched/total number
of genes in the pathway
FDR NES
Reactome Cell Cycle 127/421 0.001 0.42
Reactome G2 M Checkpoints 17/45 0.001 0.61
KEGG DNA Replication 20/36 0.001 0.65
Reactome Meiotic Recombination 35/86 0.001 0.59
Reactome Packaging of Telomere Ends 25/48 0.001 0.63
Reactome Activation of the Pre Replicative Complex 14/31 0.001 0.60
Reactome RNA POL Ι RNA POL ΙΙΙ and Mitochondrial Transcription 45/122 0.001 0.53
Reactome RNA POL Ι Transcription 35/89 0.001 0.55
Reactome RNA POL Ι Promotor Opening 32/62 0.001 0.64
Reactome Activation of ATR in Response to Replication Stress 15/38 0.001 0.63
Reactome Deposition of new CENPA containing Nucleosomes at the Centromere 34/64 0.001 0.60
Reactome DNA strand Elongation 20/30 0.001 0.69
Reactome Telomere Maintenance 39/75 0.001 0.61
Reactome Cell Cycle Mitotic 94/325 0.01 0.41
Reactome Meiosis 45/116 0.01 0.49
Reactome Amyloids 34/83 0.01 0.51
Reactome lagging strand synthesis 12/19 0.01 0.69
Reactome Mitotic M M G1 Phases 55/137 0.03 0.42
Reactome Mitotic Prometaphase 32/87 0.03 0.47
Reactome DNA replication 56/192 0.03 0.42
Reactome Meiotic Synapsis 34/73 0.03 0.50
Reactome Chromosome Maintenance 55/122 0.03 0.42
Reactome Extension of Telomeres 13/27 0.03 0.59
Reactome Transcription 61/210 0.04 0.41
PCOS women compared controls (n = 6 PCOS arrays vs n = 6 control arrays). Enriched pathways with FDR <0.05 were listed. NES = normalized enrichment score.
All enriched pathways were upregulated in PCOS CRC samples.
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ways in PCOS CRC samples.
Quantitative reverse transcriptase PCR
Five of the genes contributing to the up-regulated cell
cycle pathways in the PCOS CRCs were selected for
qRT-PCR validation. We selected genes with different
functions in the cell cycle. Gene expression by qRT-PCR
were in accordance with the microarray data for three
out of five genes tested (Figure 1). According to the
qRT-PCR results, PCOS CRC samples showed signifi-
cant up-regulation of HIST1H4C (FC = 2.7, 95% HDI
0.436-4.49), UBE2C (FC (Fold Change) = 2.6, 95% HDI
0.00438-3.21) and E2F4 (FC = 2.5, 95% HDI 0.571-5.33).
CCND2 and CCNT2 showed equal expression between
groups in the qRT-PCR experiment while the microarray
data showed a 1.4 higher expression in the PCOS CRC
samples (Figure 1).Figure 1 Comparison between microarray and qRT-PCR results for 5 s
(PCOS/controls) ± Standard Error of the Mean (SEM). Red bars represented m
experiment: 6 PCOS CRC arrays vs. 6 control CRC arrays. qRT-PCR experiment:
UBE2C, HIST1H4C and E2F4 in PCOS CRCs found in the microarray experiment
of CCND2 and CCNT2 in PCOS CRCs found in the microarray experiment couldDiscussion
In this study, we present for the first time a transcriptomic
analysis of individual human CRC samples from oocytes
used for transfer or blastocyst vitrification in PCOS and
controls. We did not find any significantly differentially
expressed individual genes after correction for multiple
testing in the present microarray study of PCOS CRCs
and control CRCs from MІІ oocytes developing into top
quality embryos. This is in contrast to the study by Haouzi
et al. [5] who found 3,700 significantly differentially
expressed genes between PCOS and control cumulus cells
from MІІ oocytes of unspecified developmental potential
with the same number of arrays per group as in the
present study (six PCOS vs. six control arrays). However,
the apparent inconsistency between the present study and
the study by Haouzi et al. [5] could be explained by the
different study designs and experimental approaches:
Firstly, we used enzymatically isolated CRCs, whichelected genes in PCOS and control CRC samples. Fold change
icroarray results and blue bars represented qRT-PCR results. Microarray
10 PCOS CRC samples vs. 10 control CRC samples. The up-regulation of
was in line with the qRT-PCR results, whereas the 1.4 fold up-regulation
not be confirmed by qRT-PCR.
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whereas Haouzi et al. [5] used mechanically cut cu-
mulus cells. Several previous studies have successfully
used enzymatically isolated cumulus cells [24-29] and
CRCs [30,31] to investigate gene expression differ-
ences according to e.g. oocyte quality. Cumulase® used
for denudation is a pure, recombinant and specific hyal-
uronidase and we would not expect the short exposure to
mask gene expression differences. To the best of our
knowledge, no studies have investigated gene expression
differences according to isolation procedure of cumulus
cells. Secondly, we used CRC samples from MІІ oocytes
capable of developing into top quality embryos, whereas
in former studies on gene expression in cumulus cells
from PCOS patients [5,6], the developmental potential of
the oocytes was not tracked. The strict use of CRCs from
MІІ oocytes developing into top quality embryos in the
present microarray study might explain why there were
no individual genes with significant differential expression
between PCOS and controls. Previous studies have shown
that the transcriptome of cumulus cells from MІІ oocytes
of poor developmental competence differed from cumulus
cells of MІІ oocytes with high developmental competence
[24,26,29,31-36]. These previous findings underlined the
importance of oocyte selection, when comparing cumulus
cells or CRCs in relation to a certain condition, such as
PCOS.
During the study period, 10% (5/51) of women diag-
nosed with PCOS did not develop embryos for transfer
or blastocyst vitrification. In the present study, we did
not examine CRCs from this minority of the PCOS pa-
tients. This might have led to an underestimation of the
differences in CRC transcriptomic profile between PCOS
patients and controls since all controls developed em-
bryos useful for transfer during the study period. Never-
theless, our data were applicable to the majority of the
PCOS patients who developed embryos suitable for
transfer: Transcriptomic aberrations found in the cumulus
cells of MІІ oocytes of unknown developmental potential
from PCOS women [5] or in the cumulus cells of the en-
tire oocyte pool from PCOS women [6] did not extrapolate
to the transcriptome of CRCs of MІІ oocytes developing
into embryos used for transfer or blastocyst vitrification.
This indicated that the microenvironment constituted by
the CRCs did not differ substantially between PCOS and
controls for oocytes with good developmental potential
and it is in line with previous findings of similar implant-
ation and pregnancy rates in PCOS patients and non-
PCOS patients undergoing IVF [8].
The minority of PCOS patients with no embryos suitable
for transfer constituted a clinically interesting subgroup
with clearly impaired oocyte quality, and future studies on
oocyte quality in PCOS should focus on this subgroup as a
distinct entity within the PCOS population.The GSEA showed up-regulation of pathways involved in
cell cycle and DNA replication in PCOS CRCs. This is in
line with previous studies showing hyperproliferative cumu-
lus [7] and granulosa [3] cells in PCOS. The LH/hCG surge
for final oocyte maturation dramatically down-regulate cell
cycle genes in human granulosa cells [37] as well as in ro-
dent cumulus-oocyte-complexes [38]. In agreement with
this, cell cycle pathways were up-regulated in human cu-
mulus cells of MІ oocytes compared to cumulus cells of
MІІ oocytes [39]. We speculate that the up-regulation of
cell cycle pathways in PCOS CRCs could be an indicator
of disturbed or delayed final maturation of the cumulus
cells/CRCs in response to the LH/hCG trigger.
The three cell cycle-related genes which showed signifi-
cant up-regulation in PCOS CRCs represented different
aspects of cell cycle: HIST1H4C is a replication-dependent
histone exclusively transcribed during the S-phase of the
cell cycle [40,41], UBE2C is required for destruction of mi-
totic cyclins and cell cycle progression [42], and E2F4 is a
transcription factor and exerted a range of functions,
mainly in cell cycle, DNA repair, ubiquitination and stress
response pathways [43]. In light of the multitude of regu-
latory functions exerted by E2F4, the significant 2.5 fold
up-regulation in PCOS CRCs according to the qRT-PCR
experiment might have interesting biological implications,
which should be explored in future studies.
Conclusion
The transcriptomic analysis of CRCs from oocytes devel-
oping into embryos selected for transfer showed up-
regulation of cell cycle pathways and DNA replication
pathways in PCOS CRC samples, however, this had no
detectable effect on in vitro development of the corre-
sponding embryos. Future studies are needed to clarify
whether the up-regulated cell cycle pathways in PCOS
CRCs have any clinical implications.
Additional files
Additional file 1: Comparison of the corona radiata cell transcriptome
between PCOS and controls (6 PCOS arrays vs. 6 control arrays).
Full gene list showing Log fold change and adjusted p-values.
Additional file 2: Comparison of the corona radiata cell transcriptome
between PCOS and controls (6 PCOS arrays vs. 6 control arrays). Here is
the full list of genes contributing to the upregulation of cell cycle pathways
in PCOS corona radiata cells. Mean intensity and fold change of each gene
is shown.
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